Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Narrative) (Details)

v3.22.1
Significant Accounting Policies (Narrative) (Details)
 12 Months Ended
Jul. 22, 2016
shares
Dec. 31, 2021
USD ($)
item
segment
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
Class of Stock [Line Items]        
Number of subsidiaries | item   0    
Number of operating segments | segment   1    
Number of reportable segments | segment   1    
Estimated useful life   5 years    
Property, plant and equipment, gross   $ 16,786,000 $ 11,595,000  
Restricted cash   1,000,000.0 1,000,000.0  
Research and development   49,864,000 37,237,000  
Accumulated other comprehensive loss   0    
Construction in Process [Member]        
Class of Stock [Line Items]        
Property, plant and equipment, gross   $ 2,027,000 $ 499,000  
Fortress Biotech, Inc [Member]        
Class of Stock [Line Items]        
Common stock dividend issued (in shares) | shares   2,001,490 2,536,607  
Percentage of fully diluted equity   2.50% 2.50%  
Fortress Biotech, Inc [Member] | At the Market Offering [Member]        
Class of Stock [Line Items]        
Percentage of fully diluted equity   2.50% 2.50% 2.50%
Fortress Biotech, Inc [Member] | License Agreements [Member]        
Class of Stock [Line Items]        
Research and development   $ 7,600,000 $ 4,200,000  
Fortress Biotech, Inc [Member] | Preferred Class A [Member]        
Class of Stock [Line Items]        
Preferred stock dividends issued (in shares) | shares 250,000      
Percentage of fully diluted equity 2.50%